

## Current Trend in Antibody-Drug Conjugates and Site-specific Trimannosyl Conjugation platform

Antibody–drug conjugates (ADC) are one of the fastest growing drug class in the next generation antibody development. Up to date, there are nine ADCs in the market against both solid tumor and hematological malignancy. With these approved drugs, the global ADC market is expected to grow from \$2.6 billion (2019) to \$24.6 billion (2026) at a 7-year compound annual growth rate (CAGR) of 37.8%. Therefore, lots of new technologies in this field have been developed including novel targets, site-specific conjugation methods, hydrophilic linkers, and novel payloads. We will discuss about the trend for the next generation ADC and introduce our unique site-specific trimannosyl conjugation platform and ADC products in DCB.